Vaccine Market By Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Vaccines), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Diphtheria, Pertussis, & Tetanus {DPT}, Polio, Hepatitis, Measles, Mumps, & Rubella {MMR}, and Other Indications), and End Use (Pediatric Vaccines, Adult Vaccines, and Traveler Vaccines): Global Opportunity Analysis and Industry Forecast, 2020–2027

1.1.Report description

1.2.Key market segments

1.2.1.List of key players profiled in the report

1.3.Research methodology

1.3.1.Primary research

1.3.2.Secondary research

1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.1.1.Top winning strategies, 2019

3.2.Top player positioning

3.2.1.Top investment pockets

3.3.Key forces shaping vaccine industry/market

3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in prevalence of infectious diseases

3.4.1.2.Surge in immunization programs across the globe

3.4.1.3.Increase in R&D activities to develop new vaccine

3.4.2.Restraint

3.4.2.1.Longer timelines required for vaccine production

3.4.2.2.High cost associated with the development of vaccine

3.4.3.Opportunity

3.4.3.1.Growth opportunities in the emerging markets

3.4.3.2.Increase in healthcare spending

3.4.4.Impact Analysis

3.1.COVID-19 impact analysis on vaccine market

3.1.1.Overview

3.1.2.Impact analysis

CHAPTER 4:VACCINE MARKET, BY TECHNOLOGY

4.1.Overview

4.1.1.Market size and forecast

4.2.Recombinant & conjugate vaccine

4.2.1.Key market trends, growth factors, and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market analysis, by country

4.3.Inactivated vaccines

4.3.1.Key market trends, growth factors, and opportunities

4.3.2.Market size and forecast, by region

4.3.3.Market analysis, by country

4.4.Live attenuated vaccines

4.4.1.Key market trends, growth factors, and opportunities

4.4.2.Market size and forecast, by region

4.4.3.Market analysis, by country

4.5.Toxoid vaccines

4.5.1.Key market trends, growth factors, and opportunities

4.5.2.Market size and forecast, by region

4.5.3.Market analysis, by country

4.6.Other vaccines

4.6.1.Key market trends, growth factors, and opportunities

4.6.2.Market size and forecast, by region

4.6.3.Market analysis, by country

CHAPTER 5:GLOBAL VACCINE MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Pneumococcal disease

5.2.1.Key market trends, growth factors, and opportunities

5.2.2.Market size and forecast, by region

5.2.3.Market analysis, by country

5.3.Influenza

5.3.1.Key market trends, growth factors, and opportunities

5.3.2.`Market size and forecast, by region

5.3.3.Market analysis, by country

5.4.Human papilloma virus

5.4.1.Key market trends, growth factors, and opportunities

5.4.2.Market size and forecast, by region

5.4.3.Market analysis, by country

5.5.Meningococcal disease

5.5.1.Key market trends, growth factors, and opportunities

5.5.2.Market size and forecast, by region

5.5.3.Market analysis, by country

5.6.Rotavirus

5.6.1.Key market trends, growth factors, and opportunities

5.6.2.Market size and forecast, by region

5.6.3.Market analysis, by country

5.7.Varicella, measles, mumps, and rubella (MMR)

5.7.1.Key market trends, growth factors, and opportunities

5.7.2.Market size and forecast, by region

5.7.3.Market analysis, by country

5.8.Diptheria, pertussis, and tetanus (DPT)

5.8.1.Key market trends, growth factors, and opportunities

5.8.2.Market size and forecast, by region

5.8.3.Market analysis, by country

5.9.Polio

5.9.1.Key market trends, growth factors, and opportunities

5.9.2.Market size and forecast, by region

5.9.3.Market analysis, by country

5.10.Hepatitis

5.10.1.Key market trends, growth factors, and opportunities

5.10.2.Market size and forecast, by region

5.10.3.Market analysis, by country

5.11.Other indications

5.11.1.Key market trends, growth factors, and opportunities

5.11.2.Market size and forecast, by region

5.11.3.Market analysis, by country

CHAPTER 6:VACCINES MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Pediatric vaccines

6.2.1.Market size and forecast

6.2.2.Market analysis, by country

6.3.Adult vaccines

6.3.1.Market size and forecast

6.3.2.Market analysis, by country

6.4.Travelers vaccines

6.4.1.Market size and forecast

6.4.2.Market analysis, by country

CHAPTER 7:GLOBAL VACCINE MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities

7.2.2.Market size and forecast, by country

7.2.3.Market size and forecast, by technology

7.2.4.Market size and forecast, by indication

7.2.5.Market size and forecast, by end user

7.2.5.1.U.S. market size and forecast, by technology

7.2.5.2.Market size and forecast, by indication

7.2.5.3.Market size and forecast, by end user

7.2.5.4.Mexico market size and forecast, by technology

7.2.5.5.Mexico market size and forecast, by indication

7.2.5.6.Mexico market size and forecast, by end user

7.2.5.7.Canada market size and forecast, by technology

7.2.5.8.Canada market size and forecast, by indication

7.2.5.9.Canada market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities

7.3.2.Market size and forecast, by country

7.3.3.Market size and forecast, by technology

7.3.4.Market size and forecast, by indication

7.3.5.Market size and forecast, by end user

7.3.5.1.Germany market size and forecast, by technology

7.3.5.2.Germany market size and forecast, by indication

7.3.5.3.Germany market size and forecast, by end user

7.3.5.4.France market size and forecast, by technology

7.3.5.5.France market size and forecast, by indication

7.3.5.6.France market size and forecast, by end user

7.3.5.7.UK market size and forecast, by technology

7.3.5.8.UK market size and forecast, by indication

7.3.5.9.UK market size and forecast, by end user

7.3.5.10.Italy market size and forecast, by technology

7.3.5.11.Italy market size and forecast, by indication

7.3.5.12.Italy market size and forecast, by end user

7.3.5.13.Spain market size and forecast, by technology

7.3.5.14.Spain market size and forecast, by indication

7.3.5.15.Spain market size and forecast, by end user

7.3.5.16.Rest of Europe market size and forecast, by technology

7.3.5.17.Rest of Europe market size and forecast, by indication

7.3.5.18.Rest of Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities

7.4.2.Market size and forecast, by country

7.4.3.Market size and forecast, by technology

7.4.4.Market size and forecast, by indication

7.4.5.Market size and forecast, by end user

7.4.5.1.Japan market size and forecast, by technology

7.4.5.2.Japan market size and forecast, by indication

7.4.5.3.Japan market size and forecast, by end user

7.4.5.4.China market size and forecast, by technology

7.4.5.5.China market size and forecast, by indication

7.4.5.6.China market size and forecast, by end user

7.4.5.7.India market size and forecast, by technology

7.4.5.8.India market size and forecast, by indication

7.4.5.9.India market size and forecast, by end user

7.4.5.10.Australia market size and forecast, by technology

7.4.5.11.Australia market size and forecast, by indication

7.4.5.12.Australia market size and forecast, by end user

7.4.5.13.Rest of Asia-Pacific market size and forecast, by technology

7.4.5.14.Rest of Asia-Pacific market size and forecast, by indication

7.4.5.15.Rest of Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities

7.5.2.Market size and forecast, by country

7.5.3.Market size and forecast, by technology

7.5.4.Market size and forecast, by indication

7.5.5.Market size and forecast, by end user

7.5.5.1.Brazil market size and forecast, by technology

7.5.5.2.Brazil market size and forecast, by indication

7.5.5.3.Brazil market size and forecast, by end user

7.5.5.4.Saudi Arabia market size and forecast, by technology

7.5.5.5.Saudi Arabia market size and forecast, by indication

7.5.5.6.Saudi Arabia market size and forecast, by end user

7.5.5.7.South Africa market size and forecast, by technology

7.5.5.8.South Africa market size and forecast, by indication

7.5.5.9.South Africa market size and forecast, by end user

7.5.5.10.Rest of LAMEA market size and forecast, by technology

7.5.5.11.Rest of LAMEA market size and forecast, by indication

7.5.5.12.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.AstraZeneca plc.

8.1.1.Company overview

8.1.2.Company snapshot

8.1.3.Product portfolio

8.1.4.Business performance

8.2.CSL Limited

8.2.1.Company overview

8.2.2.Company snapshot

8.2.3.Operating business segments

8.2.4.Product portfolio

8.2.5.Business performance

8.3.Emergent BioSolutions Inc.

8.3.1.Company overview

8.3.2.Company snapshot

8.3.3.Operating business segments

8.3.4.Product portfolio

8.3.5.Business performance

8.3.1.Key strategic moves and developments

8.4.GlaxoSmithKline plc.

8.4.1.Company overview

8.4.2.Company snapshot

8.4.3.Operating business segments

8.4.4.Product portfolio

8.4.5.Business performance

8.4.6.Key strategic moves and developments

8.5.Johnson & Johnson

8.5.1.Company overview

8.5.2.Company snapshot

8.5.3.Operating business segments

8.5.4.Product portfolio

8.5.5.Business performance

8.5.6.Key strategic moves and developments

8.6.MERCK & CO. INC.

8.6.1.Company overview

8.6.2.Company snapshot

8.6.3.Operating business segments

8.6.4.Product portfolio

8.6.5.Business performance

8.6.6.Key strategic moves and developments

8.7.NOVAVAX, INC.

8.7.1.Company overview

8.7.2.Company snapshot

8.7.3.Operating business segments

8.7.4.Product portfolio

8.7.5.Business performance

8.8.PFIZER INC.

8.8.1.Company overview

8.8.2.Company snapshot

8.8.3.Operating business segments

8.8.4.Product portfolio

8.8.5.Business performance

8.8.6.Key strategic moves and developments

8.9.Sanofi S.A.

8.9.1.Company overview

8.9.2.Company snapshot

8.9.3.Operating business segments

8.9.4.Product portfolio

8.9.5.Business performance

8.9.6.Key strategic moves and developments

8.10.SERUM INSTITUTE OF INDIA PVT. LTD

8.10.1.Company overview

8.10.2.Company snapshot

8.10.3.Operating business segments

8.10.4.Product portfolio

TABLE 01.GLOBAL VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 02.RECOMBINANT & CONJUGATE VACCINE MARKET, BY REGION, 2019–2027 ($MILLION)

TABLE 03.INACTIVATED VACCINE, BY REGION, 2019–2027 ($MILLION)

TABLE 04.LIVE ATTENUATED VACCINE, BY REGION, 2019–2027 ($MILLION)

TABLE 05.TOXOID VACCINE, BY REGION, 2019–2027 ($MILLION)

TABLE 06.VACCINE MARKET FOR OTHER VACCINES, BY REGION, 2019–2027 ($MILLION)

TABLE 07.GLOBAL VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 08.VACCINE MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2019–2027 ($MILLION)

TABLE 09.VACCINE MARKET FOR INFLUENZA, BY REGION, 2019–2027 ($MILLION)

TABLE 10.VACCINE MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2019–2027 ($MILLION)

TABLE 11.VACCINE MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2019–2027 ($MILLION)

TABLE 12.VACCINE MARKET FOR ROTAVIRUS DISEASE, BY REGION, 2019–2027 ($MILLION)

TABLE 13.VACCINE MARKET FOR VARICELLA, MEASLES, MUMPS, AND RUBELLA (MMR), BY REGION, 2019–2027 ($MILLION)

TABLE 14.VACCINE MARKET FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY REGION, 2019–2027 ($MILLION)

TABLE 15.VACCINE MARKET FOR POLIO, BY REGION, 2019–2027 ($MILLION)

TABLE 16.VACCINE MARKET FOR HEPATITIS, BY REGION, 2019–2027 ($MILLION)

TABLE 17.VACCINE MARKET FOROTHER INDICATION, BY REGION, 2019–2027 ($MILLION)

TABLE 18.GLOBAL VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 19.VACCINE MARKET FOR PEDIATRIC, BY REGION, 2019–2027 ($MILLION)

TABLE 20.VACCINE MARKET FOR ADULTS VACCINES, BY REGION, 2019–2027 ($MILLION)

TABLE 21.VACCINE MARKET FOR TRAVELERS VACCINES, BY REGION, 2019–2027 ($MILLION)

TABLE 22.VACCINE MARKET, BY REGION, 2019–2027 ($MILLION)

TABLE 23.NORTH AMERICA VACCINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 24.NORTH AMERICA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 25.NORTH AMERICA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 26.NORTH AMERICA MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 27.U.S. VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 28.U.S. VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 29.U.S. VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 30.MEXICO VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 31.MEXICO VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 32.MEXICO VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 33.CANADA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 34.CANADA VACCINE MARKET, BY INDICATION , 2019–2027 ($MILLION)

TABLE 35.CANADA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 36.EUROPE VACCINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 37.EUROPE VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 38.EUROPE VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 39.EUROPE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 40.GERMANY VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 41.GERMANY VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 42.GERMANY VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 43.FRANCE VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 44.FRANCE VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 45.FRANCE VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 46.UK VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 47.UK VACCINE MARKET, BY INDICATION , 2019–2027 ($MILLION)

TABLE 48.UK VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 49.ITALY VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 50.ITALY VACCINE MARKET, BY INDICATION , 2019–2027 ($MILLION)

TABLE 51.ITALY VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 52.SPAIN VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 53.SPAIN VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 54.SPAIN VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 55.REST OF EUROPE VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 56.REST OF EUROPE VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 57.REST OF EUROPE VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 58.ASIA-PACIFIC VACCINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 59.ASIA-PACIFIC VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 60.ASIA-PACIFIC VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 61.ASIA-PACIFIC MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 62.JAPAN VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 63.JAPAN VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 64.JAPAN VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 65.CHINA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 66.CHINA VACCINE MARKET, BY INDICATION , 2019–2027 ($MILLION)

TABLE 67.CHINA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 68.INDIA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 69.INDIA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 70.INDIA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 71.AUSTRALIA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 72.AUSTRALIA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 73.AUSTRALIA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 74.REST OF ASIA-PACIFIC VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 75.REST OF ASIA-PACIFIC VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 76.REST OF ASIA-PACIFIC VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 77.LAMEA VACCINE MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 78.LAMEA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 79.LAMEA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 80.LAMEA MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 81.BRAZIL VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 82.BRAZIL VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 83.BRAZIL VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 84.SAUDI ARABIA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 85.SAUDI ARABIA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 86.SAUDI ARABIA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 87.SOUTH AFRICA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 88.SOUTH AFRICA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 89.SOUTH AFRICA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 90.REST OF LAMEA VACCINE MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)

TABLE 91.REST OF LAMEA VACCINE MARKET, BY INDICATION, 2019–2027 ($MILLION)

TABLE 92.REST OF LAMEA VACCINE MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 93.ASTRAZENECA: COMPANY SNAPSHOT

TABLE 94.ASTRAZENECA: PRODUCT PORTFOLIO

TABLE 95.CSL: COMPANY SNAPSHOT

TABLE 96.CSL: OPERATING SEGMENTS

TABLE 97.CSL: PRODUCT PORTFOLIO

TABLE 98.EMERGENT SOLUTIONS: COMPANY SNAPSHOT

TABLE 99.EMERGENT SOLUTIONS: OPERATING SEGMENTS

TABLE 100.EMERGENT SOLUTIONS: PRODUCT PORTFOLIO

TABLE 101.GSK: COMPANY SNAPSHOT

TABLE 102.GSK: OPERATING SEGMENTS

TABLE 103.GSK: PRODUCT PORTFOLIO

TABLE 104.J&J: COMPANY SNAPSHOT

TABLE 105.J&J: OPERATING SEGMENTS

TABLE 106.J&J: PRODUCT PORTFOLIO

TABLE 107.MERCK: COMPANY SNAPSHOT

TABLE 108.MERCK: OPERATING SEGMENTS

TABLE 109.MERCK: PRODUCT PORTFOLIO

TABLE 110.NOVAVAX: COMPANY SNAPSHOT

TABLE 111.NOVAVAX: PRODUCT PORTFOLIO:

TABLE 112.PFIZER: COMPANY SNAPSHOT

TABLE 113.PFIZER: OPERATING SEGMENTS

TABLE 114.PFIZER: PRODUCT PORTFOLIO

TABLE 115.SANOFI: COMPANY SNAPSHOT

TABLE 116.SANOFI S.A.: OPERATING SEGMENTS

TABLE 117.SANOFI S.A.: PRODUCT PORTFOLIO

TABLE 118.SERUM INSTITUTE: COMPANY SNAPSHOT

TABLE 119.SERUM INSTITUTE: PRODUCT PORTFOLIO